Anti-Mouse NKG2A/C/E In Vivo Antibody - Low Endotoxin

(No reviews yet) Write a Review

제품 코드를 사용하여 Assay Genie 메인 사이트를 통해 주문합니다.

주문
SKU:
IVMB0385
Product Type:
In Vivo Monoclonal Antibody
Clone:
20D5
Protein:
NKG2a
Isotype:
IgG2a k
Reactivity:
Mouse
Synonyms:
CD159a
Synonyms:
CD159c
Synonyms:
CD159e
Synonyms:
NKG2C
Synonyms:
NKG2E
Research Area:
Cell Biology
Research Area:
Immunology
Research Area:
Signal Transduction
Research Area:
Stem Cell
Endotoxin Level:
Low Endotoxin
Host Species:
Rat
Applications:
Blocking
Applications:
FC
Applications:
IHC
Applications:
In Vivo
€0.00
Frequently bought together:

Description

Product Name:Anti-Mouse NKG2A/C/E In Vivo Antibody - Low Endotoxin
Product Code:IVMB0385
Size:1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:20D5
Protein:NKG2a
Product Type:Monoclonal Antibody
Synonyms:CD159a, CD159c, CD159e, NKG2C, NKG2E
Isotype:IgG2a k
Reactivity:Mouse
Applications:B, FC, IHC, In Vivo
Formulation:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC ⋅ >95% by SDS Page
Product Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:B, FC, IHC, In Vivo
Reactivity:Mouse
Host Species:Rat
Specificity:Clone 20D5 recognizes an epitope on the mouse NKG2A, NKG2C, and NKG2E isoforms of the CD94/NKG2 heterodimer. DBA/2J mice are CD94-deficient and do not express CD94/NKG2 receptors.
Antigen Distribution:NKG2A/C/E is expressed on NK cells, NKT cells, and activated CD8 T cells.
Immunogen:CHO transfected cells expressing the C57BL/6 allele of NKG2A and CD94
Concentration:≥ 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Formulation:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:≥95% monomer by analytical SEC ⋅ >95% by SDS Page
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

NKG2A/C/E antibody, clone 20D5, recognizes the NKG2A, NKG2C, and NKG2E isoforms (also known as CD159a, CD159c,m CD159e, respectively) of the NKG2 receptor, belonging to the C-type lectin-like family. NKG2 receptors are expressed at the cell surface as a heterodimer with CD94 and recognize the non-classical class I MHC-1 molecules HLA-E in humans and Qa-1 in mice1-4. NKG2A/C/E are expressed on natural killer (NK) cells, NKT cells, and activated CD8 T cells5-6. Engagement of NKG2A/CD94 transduces an inhibitory signal, blocking NK and CD8 T cell cytotoxicity and promoting self-tolerance7. In contrast, NKG2C/CD94 and NKGE/CD94 are activating receptors8 and bind with lower affinity to HLA-E9. Cancer cells frequently overexpress HLA-E to protect against NK/CD8 T cell killing, and blocking NKG2 receptors in mice promotes anti-tumor immunity and may enhance the cytotoxic potential of other therapeutic antibodies10,11. The NKG2 receptor antibody monalizumab is currently in phase III clinical trials (INTERLINK-1) in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Protein:NKG2a
Function:Inhibitory activity via ITIMs
Research Area:Cell Biology, Immunology, Signal Transduction, Stem Cell
Shipping:2-8°C
Molecular Weight:150 kDa
View AllClose

Related Products